{"id":"mitomycin-mm","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (bone marrow suppression)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Hemolytic uremic syndrome"},{"rate":null,"effect":"Pulmonary toxicity"},{"rate":null,"effect":"Nephrotoxicity"}]},"_chembl":{"chemblId":"CHEMBL4114182","moleculeType":"Small molecule","molecularWeight":"518.67"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mitomycin acts as a DNA-damaging agent by forming covalent cross-links between DNA strands after bioreductive activation. This prevents DNA replication and transcription, leading to cell cycle arrest and programmed cell death. It is primarily used in cancer therapy due to its potent cytotoxic effects on rapidly dividing cells.","oneSentence":"Mitomycin is an antibiotic that alkylates DNA, causing cross-linking and strand breaks that prevent cell division and induce apoptosis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:21:37.504Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastric cancer"},{"name":"Colorectal cancer"},{"name":"Bladder cancer"},{"name":"Breast cancer"}]},"trialDetails":[{"nctId":"NCT07487168","phase":"PHASE1","title":"Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2026-03","conditions":"Peritoneal Carcinomatosis","enrollment":24},{"nctId":"NCT07425743","phase":"NA","title":"Conventional Non-Penetrating Deep Sclerectomy Versus Modified Subflap Mattress Suture in OAG","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2022-11-07","conditions":"Open Angle Glaucoma (OAG)","enrollment":26},{"nctId":"NCT06783491","phase":"PHASE3","title":"Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer","status":"NOT_YET_RECRUITING","sponsor":"Maimónides Biomedical Research Institute of Córdoba","startDate":"2025-12-31","conditions":"Locally Advanced Colorectal Cancer","enrollment":1083},{"nctId":"NCT07173023","phase":"NA","title":"A Comparative Study of Endoscopic Choanal Canalization and Mitomycin C Application vs Endoscopic Crossover Flap Technique","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-09","conditions":"Choanal Atresia","enrollment":30},{"nctId":"NCT06393855","phase":"NA","title":"Base Curves of Bandage Contact Lenses and Their Effects on Post Trans-PRK Vision and Pain","status":"RECRUITING","sponsor":"Dongyang People's Hospital","startDate":"2024-06-18","conditions":"Myopia","enrollment":36},{"nctId":"NCT06462001","phase":"PHASE3","title":"BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nottingham University Hospitals NHS Trust","startDate":"2020-12-10","conditions":"Transitional Cell Carcinoma, Transurethral Resection","enrollment":500},{"nctId":"NCT02948543","phase":"PHASE3","title":"Adding Mitomycin to BCG as Adjuvant Intravesical Therapy for High-risk Non-Muscle-invasive Bladder Cancer","status":"UNKNOWN","sponsor":"University of Sydney","startDate":"2013-07","conditions":"Bladder Cancer","enrollment":501},{"nctId":"NCT03480711","phase":"NA","title":"Modified Trabeculectomy With an ESST Versus Conventional SST for Management of Primary Open Angle Glaucoma","status":"COMPLETED","sponsor":"Rehab mahmoud abdelhamid mohamed","startDate":"2018-07-10","conditions":"Primary Open-angle Glaucoma","enrollment":40},{"nctId":"NCT04493073","phase":"EARLY_PHASE1","title":"Conjunctival Vascularity Changes Usnig OCTA After Trabeculectomy","status":"UNKNOWN","sponsor":"Asmaa Ahmed Ali Youssif","startDate":"2020-12-01","conditions":"OCTA","enrollment":100},{"nctId":"NCT04417920","phase":"NA","title":"Express Implant Versus Trabeculectomy After Late Failure Trabeculectomy","status":"COMPLETED","sponsor":"Menoufia University","startDate":"2017-07-01","conditions":"Glaucoma","enrollment":28},{"nctId":"NCT04214847","phase":"NA","title":"The Outcome of Ahmed Glaucoma Valve in Difficult Glaucoma Cases","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2012-02-01","conditions":"Glaucoma, Open-Angle, Glaucoma Secondary, Glaucoma, Neovascular","enrollment":1},{"nctId":"NCT03780868","phase":"NA","title":"External DCR Versus Canalicular SI With MMC in NLDO","status":"COMPLETED","sponsor":"Menoufia University","startDate":"2012-06-01","conditions":"Primary Acquired Nasolacrimal Duct Obstruction","enrollment":56},{"nctId":"NCT01527721","phase":"NA","title":"Blurring Strength & Aberrometric Changes Following Corneal Cross-linking (CxL) and CxL Combined With Photorefractive Keratectomy (PRK) in Keratoconus","status":"COMPLETED","sponsor":"Democritus University of Thrace","startDate":"2010-09","conditions":"Keratoconus","enrollment":32},{"nctId":"NCT02638376","phase":"PHASE3","title":"Evaluating the Safety and Efficacy of the KXL System for Corneal Collagen Cross-Linking in Eyes Having Keratoconus","status":"UNKNOWN","sponsor":"Singapore Eye Research Institute","startDate":"2013-03","conditions":"Keratoconus, Post LASIK Keratectasia","enrollment":66},{"nctId":"NCT00306852","phase":"NA","title":"Tube Versus Trabeculectomy (TVT) Study","status":"COMPLETED","sponsor":"University of Miami","startDate":"1999-10","conditions":"Glaucoma","enrollment":212},{"nctId":"NCT00538590","phase":"PHASE4","title":"Ologen Collagen Matrix Safety and Effective Comparison With Mitomycin-C(MMC) in Glaucoma Surgery","status":"COMPLETED","sponsor":"Pro Top & Mediking Company Limited","startDate":"2007-07","conditions":"Open Angle Glaucoma","enrollment":20},{"nctId":"NCT00472810","phase":"PHASE3","title":"Ologen (OculusGen)-Glaucoma MMC Control in Pakistan","status":"COMPLETED","sponsor":"Pro Top & Mediking Company Limited","startDate":"2007-03","conditions":"Glaucoma, Trabeculectomy","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Mitomycin (MM)","genericName":"Mitomycin (MM)","companyName":"University of Sydney","companyId":"university-of-sydney","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mitomycin is an antibiotic that alkylates DNA, causing cross-linking and strand breaks that prevent cell division and induce apoptosis. Used for Gastric cancer, Colorectal cancer, Bladder cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}